Discover Toleroxyl™, Vytrus Biotech’s latest biotech launch at in-cosmetics Korea 2026. This new active introduces the concept of immune re-education in cosmetics, helping hyperreactive urban skin restore tolerance, comfort and visible resilience by targeting Langerhans cells.
The cosmetics industry is entering a new era in sensitive skin care, where the goal is no longer only to soothe, calm or mask visible reactivity, but to help the skin recover its own ability to tolerate daily stressors. At in-cosmetics Korea 2026, Vytrus Biotech will be exhibiting and launching Toleroxyl™ – Re-educating urban skin, a new biotech active designed to open a new cosmetic category: the Tolerogen.
Sensitive skin is one of today’s fastest-growing consumer concerns. Modern lifestyles, indoor environments and continuous exposure to low-grade pollutants are contributing to redness, tightness, burning, stinging and discomfort. Many consumers describe skin that “overreacts to everything” or “never stays calm for long”. For Vytrus, this reflects a deeper biological challenge: the skin has not necessarily become weaker; it may have lost its ability to distinguish harmless urban stressors from real threats.
Toleroxyl™ proposes a new cosmetic logic: train the skin, do not just silence it. Developed through Vytrus’ biotechnology platforms, the active is inspired by the skin’s own biological signals and targets Langerhans cells, the immune decision-makers of the epidermis. These cells play a central role in determining whether the skin responds with inflammation or tolerance.
The active works through a precise mechanism based on GM-CSF, a human protein involved in the differentiation, survival and functional programming of Langerhans cells. By binding to GM-CSF receptors on Langerhans cells, Toleroxyl™ helps keep them in a calm, tolerance-supporting state. Calmed Langerhans cells promote the release of TGF-β, helping reduce inflammatory signals such as TNF-α, IL-8 and IL-6, and supporting a healthier, non-inflamed skin environment.
In vitro studies have shown that Toleroxyl™ activates key tolerogenic pathways by restoring RELB and SOX4, while helping normalize immunogenic markers such as CCR7, CD80 and CD86. It also reinforces the skin barrier by supporting structural markers including Filaggrin, Loricrin and Claudin-4.
Clinical studies in volunteers with hyperreactive skin demonstrated visible benefits, including redness reduction, erythema improvement and relief from discomfort-related signs such as stinging, itching, burning and tightness. In vivo cytokine regulation also showed a reduction of pro-inflammatory markers in volunteers with hyperreactive skin (IL-8, TNF-α and IL-6).
For cosmetic formulators, Toleroxyl™ opens new opportunities in tolerance-training skin care, anti-redness serums, anti-pollution daily care, barrier-support routines and recovery products for overstimulated urban skin.
With Toleroxyl™, Vytrus Biotech introduces a new way to address sensitive skin: not by masking the signal, but by helping skin relearn tolerance. Discover this new biotech active at in-cosmetics Korea 2026 in Seoul or contact Vytrus Biotech team at customer@vytrus.com for further information.
Website: www.vytrus.com
E-mail: customer@vytrus.com
